NeuroBo Pharmaceuticals PE Ratio 1970-1969 | MTVA
Current and historical p/e ratio for NeuroBo Pharmaceuticals (MTVA) from 1970 to 1969. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. NeuroBo Pharmaceuticals PE ratio as of November 29, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| NeuroBo Pharmaceuticals PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
|
0.00 |
|
nan |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.022B |
$0.000B |
|
NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States.
|
